RU2221795C2 - Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения - Google Patents
Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения Download PDFInfo
- Publication number
- RU2221795C2 RU2221795C2 RU2000100951/04A RU2000100951A RU2221795C2 RU 2221795 C2 RU2221795 C2 RU 2221795C2 RU 2000100951/04 A RU2000100951/04 A RU 2000100951/04A RU 2000100951 A RU2000100951 A RU 2000100951A RU 2221795 C2 RU2221795 C2 RU 2221795C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- alkyl
- aryl
- denotes
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 36
- 238000000034 method Methods 0.000 title claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 14
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000012453 solvate Substances 0.000 claims abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims abstract 4
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims abstract 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- -1 Imidazolyl cyclic acetals Chemical class 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 229910005965 SO 2 Inorganic materials 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims 2
- RERSCSYZEKLVHG-UHFFFAOYSA-N [2-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(4-fluorophenyl)-1h-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-morpholin-4-ylmethanone Chemical compound O1CC(C)(C(=O)N2CCOCC2)COC1C(N1)=NC(C=2C=CC(F)=CC=2)=C1C(N=1)=CC=NC=1NC1CC1 RERSCSYZEKLVHG-UHFFFAOYSA-N 0.000 claims 2
- LHVMOVISOAUTPX-UHFFFAOYSA-N [2-[5-[2-(cyclopropylmethylamino)pyrimidin-4-yl]-4-(4-fluorophenyl)-1h-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1(C)COC(C=2NC(=C(N=2)C=2C=CC(F)=CC=2)C=2N=C(NCC3CC3)N=CC=2)OC1 LHVMOVISOAUTPX-UHFFFAOYSA-N 0.000 claims 2
- 125000005518 carboxamido group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- CGLFSRLSKUVUDU-UHFFFAOYSA-N n-cyclopropyl-2-[4-(4-fluorophenyl)-5-[2-(propylamino)pyrimidin-4-yl]-1h-imidazol-2-yl]-5-methyl-1,3-dioxane-5-carboxamide Chemical compound CCCNC1=NC=CC(C2=C(N=C(N2)C2OCC(C)(CO2)C(=O)NC2CC2)C=2C=CC(F)=CC=2)=N1 CGLFSRLSKUVUDU-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 0 CC(C=I)Nc1nc(-c2c(C(CC3)=C*=C3F)[n]c([C@](OC3)OC[C@]3(*I)C(NCCN(C=I)O)=O)n2)ccn1 Chemical compound CC(C=I)Nc1nc(-c2c(C(CC3)=C*=C3F)[n]c([C@](OC3)OC[C@]3(*I)C(NCCN(C=I)O)=O)n2)ccn1 0.000 description 11
- YNNIOZXWMARNSA-QNYFIVLPSA-N CC(C#C)Nc1nc(-c2c(-c(cc3)ccc3F)[nH]c([C@H](OC3)OC[C@@]3(C)C(N3CCN(C)CC3)=O)n2)ccn1 Chemical compound CC(C#C)Nc1nc(-c2c(-c(cc3)ccc3F)[nH]c([C@H](OC3)OC[C@@]3(C)C(N3CCN(C)CC3)=O)n2)ccn1 YNNIOZXWMARNSA-QNYFIVLPSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9712270.09 | 1997-06-12 | ||
| GBGB9712270.9A GB9712270D0 (en) | 1997-06-12 | 1997-06-12 | Chemical compounds |
| US5218597P | 1997-07-10 | 1997-07-10 | |
| US60/052,185 | 1997-07-10 | ||
| GBGB9724678.9A GB9724678D0 (en) | 1997-11-21 | 1997-11-21 | Chemical compounds |
| GB9724678.9 | 1997-11-21 | ||
| US8549998P | 1998-05-14 | 1998-05-14 | |
| US60/085,499 | 1998-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000100951A RU2000100951A (ru) | 2002-08-10 |
| RU2221795C2 true RU2221795C2 (ru) | 2004-01-20 |
Family
ID=27451664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000100951/04A RU2221795C2 (ru) | 1997-06-12 | 1998-06-12 | Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6602877B1 (enExample) |
| EP (1) | EP0988301B1 (enExample) |
| JP (1) | JP4380803B2 (enExample) |
| KR (1) | KR100704059B1 (enExample) |
| CN (1) | CN100443481C (enExample) |
| AT (1) | ATE335735T1 (enExample) |
| AU (1) | AU742293B2 (enExample) |
| BR (1) | BR9810007B1 (enExample) |
| CA (1) | CA2293436C (enExample) |
| CY (1) | CY1105238T1 (enExample) |
| CZ (1) | CZ9904452A3 (enExample) |
| DE (1) | DE69835518T2 (enExample) |
| DK (1) | DK0988301T3 (enExample) |
| ES (1) | ES2270520T3 (enExample) |
| HU (1) | HUP0003309A3 (enExample) |
| IL (2) | IL133311A0 (enExample) |
| NO (1) | NO326660B1 (enExample) |
| NZ (1) | NZ501714A (enExample) |
| PL (1) | PL199893B1 (enExample) |
| PT (1) | PT988301E (enExample) |
| RU (1) | RU2221795C2 (enExample) |
| SK (2) | SK286940B6 (enExample) |
| TR (1) | TR199903098T2 (enExample) |
| TW (1) | TWI235751B (enExample) |
| WO (1) | WO1998056788A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US6599910B1 (en) * | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
| ES2270612T3 (es) | 1998-08-29 | 2007-04-01 | Astrazeneca Ab | Compuestos de pirimidina. |
| AU5438299A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| JP2002528506A (ja) | 1998-11-04 | 2002-09-03 | スミスクライン・ビーチャム・コーポレイション | ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン |
| DE69903976T2 (de) * | 1998-12-16 | 2003-07-24 | Aventis Pharma Ltd | Heteroaryl-zyklische acetale |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| US6291457B1 (en) | 1999-07-01 | 2001-09-18 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| IL149150A0 (en) * | 1999-11-22 | 2002-12-01 | Smithkline Beecham Plc | 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors |
| US6759410B1 (en) * | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
| AU1783201A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| DE60023025T2 (de) | 1999-11-23 | 2006-07-13 | Smithkline Beecham Corp. | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren |
| JP2003514899A (ja) | 1999-11-23 | 2003-04-22 | スミスクライン・ビーチャム・コーポレイション | ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物 |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0100762D0 (en) * | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| CA2437248A1 (en) * | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| ES2706902T3 (es) | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| WO2003022837A1 (en) * | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| DE60310730T2 (de) | 2002-07-09 | 2007-05-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TWI317286B (en) | 2003-12-31 | 2009-11-21 | Targeting delivery system | |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
| EP1943238A1 (en) * | 2005-10-24 | 2008-07-16 | F.Hoffmann-La Roche Ag | Preparation of cyclic, ketalized ketones by favorskii rearrangement and the use thereof for the preparation of glucokinase activator 70 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| KR20120016247A (ko) * | 2009-05-19 | 2012-02-23 | 다우 아그로사이언시즈 엘엘씨 | 진균 방제를 위한 화합물 및 방법 |
| CN111356687B (zh) * | 2019-03-27 | 2021-03-30 | 广州必贝特医药技术有限公司 | 含嘧啶的三取代咪唑类化合物及其应用 |
| JP2023517944A (ja) | 2020-03-11 | 2023-04-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| US3940486A (en) | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
| US4175127A (en) | 1978-09-27 | 1979-11-20 | Smithkline Corporation | Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles |
| WO1983002613A1 (fr) | 1981-07-20 | 1983-08-04 | Sallmann, Alfred | Composes oxazoiques a triple substitution |
| US4503065A (en) | 1982-08-03 | 1985-03-05 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl 1-2-halo imidazoles |
| US4728656A (en) | 1985-12-12 | 1988-03-01 | Smithkline Beckman Corporation | 2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway |
| US4686231A (en) | 1985-12-12 | 1987-08-11 | Smithkline Beckman Corporation | Inhibition of 5-lipoxygenase products |
| EP0264883A3 (en) | 1986-10-21 | 1990-04-04 | Banyu Pharmaceutical Co., Ltd. | Substituted pyridine derivatives |
| IL84492A0 (en) | 1986-11-21 | 1988-04-29 | Ciba Geigy Ag | Unsaturated phosphonic acids and derivatives |
| US4837350A (en) | 1986-12-15 | 1989-06-06 | Ciba-Geigy Corporation | Process for the preparation of benzoin sulfonates |
| US5109002A (en) | 1989-09-08 | 1992-04-28 | Du Pont Merck Pharmaceutical Company | Antipsychotic 1-cycloalkylpiperidines |
| IL95760A0 (en) * | 1989-09-27 | 1992-05-25 | Rhone Poulenc Sante | Imidazole derivatives,their preparation and pharmaceutical compositions containing the same |
| GB9020889D0 (en) * | 1990-09-25 | 1990-11-07 | May & Baker Ltd | New compositions of matter |
| US5102848A (en) | 1990-09-28 | 1992-04-07 | Union Carbide Chemicals & Plastics Technology Corporation | Catalyst composition for oxidation of ethylene to ethylene oxide |
| GB9106508D0 (en) * | 1991-03-27 | 1991-05-15 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| US5179117A (en) | 1991-12-20 | 1993-01-12 | Du Pont Merck Pharmaceutical Company | Antihypercholesterolemic 2-substituted imidazoles |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| AU3592493A (en) * | 1992-01-13 | 1993-08-03 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| US5364875A (en) | 1992-05-11 | 1994-11-15 | The Du Pont Merck Pharmaceutical Company | Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis |
| GB9303993D0 (en) | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
| US5593991A (en) | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
| US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
| US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| AU7629594A (en) | 1993-07-21 | 1995-02-20 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| JPH0753546A (ja) | 1993-08-09 | 1995-02-28 | Kuraray Co Ltd | ジアリール置換複素環化合物およびその医薬用途 |
| DE69433501T2 (de) | 1993-11-08 | 2004-11-04 | Smithkline Beecham Corp. | Oxazole zur behandlung von zytokinvermittelten erkrankungen |
| DE69401486T2 (de) | 1993-11-12 | 1997-04-30 | Ishihara Sangyo Kaisha | Verfahren zur Herstellung 2-cyanoimidazol Derivate |
| CN1088062C (zh) | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
| ES2193256T3 (es) | 1995-08-10 | 2003-11-01 | Merck & Co Inc | Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso. |
| WO1997005878A1 (en) | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| JPH09124640A (ja) | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| EE03681B1 (et) | 1995-10-06 | 2002-04-15 | Merck & Co., Inc. | Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime |
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| WO1997016441A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| AU7529096A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| WO1997016442A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| JP3912758B2 (ja) | 1996-02-16 | 2007-05-09 | 富士フイルム株式会社 | １，１−ジ置換−１Ｈ−ベンゾ〔ｅ〕インドール化合物の製造方法及び４〜９位ヒドロキシ基置換の該化合物 |
| JP2000507545A (ja) | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Ｃｎｓ損傷についての新規な治療 |
| GB0515625D0 (en) | 2005-07-29 | 2005-09-07 | Univ Manchester | Hydrogel particle |
-
1998
- 1998-06-12 SK SK3-2009A patent/SK286940B6/sk not_active IP Right Cessation
- 1998-06-12 CZ CZ19994452A patent/CZ9904452A3/cs unknown
- 1998-06-12 NZ NZ501714A patent/NZ501714A/xx not_active IP Right Cessation
- 1998-06-12 AU AU79259/98A patent/AU742293B2/en not_active Ceased
- 1998-06-12 AT AT98929548T patent/ATE335735T1/de active
- 1998-06-12 KR KR1019997011695A patent/KR100704059B1/ko not_active Expired - Fee Related
- 1998-06-12 HU HU0003309A patent/HUP0003309A3/hu unknown
- 1998-06-12 BR BRPI9810007-6A patent/BR9810007B1/pt not_active IP Right Cessation
- 1998-06-12 CA CA2293436A patent/CA2293436C/en not_active Expired - Fee Related
- 1998-06-12 PT PT98929548T patent/PT988301E/pt unknown
- 1998-06-12 TR TR1999/03098T patent/TR199903098T2/xx unknown
- 1998-06-12 IL IL13331198A patent/IL133311A0/xx active IP Right Grant
- 1998-06-12 DE DE69835518T patent/DE69835518T2/de not_active Expired - Lifetime
- 1998-06-12 PL PL337314A patent/PL199893B1/pl not_active IP Right Cessation
- 1998-06-12 RU RU2000100951/04A patent/RU2221795C2/ru not_active IP Right Cessation
- 1998-06-12 ES ES98929548T patent/ES2270520T3/es not_active Expired - Lifetime
- 1998-06-12 DK DK98929548T patent/DK0988301T3/da active
- 1998-06-12 WO PCT/GB1998/001711 patent/WO1998056788A1/en not_active Ceased
- 1998-06-12 JP JP50190899A patent/JP4380803B2/ja not_active Expired - Lifetime
- 1998-06-12 SK SK1710-99A patent/SK171099A3/sk unknown
- 1998-06-12 EP EP98929548A patent/EP0988301B1/en not_active Expired - Lifetime
- 1998-06-12 CN CNB988079119A patent/CN100443481C/zh not_active Expired - Fee Related
- 1998-07-29 TW TW087112466A patent/TWI235751B/zh not_active IP Right Cessation
-
1999
- 1999-12-05 IL IL133311A patent/IL133311A/en not_active IP Right Cessation
- 1999-12-08 US US09/456,360 patent/US6602877B1/en not_active Expired - Lifetime
- 1999-12-10 NO NO996120A patent/NO326660B1/no not_active IP Right Cessation
-
2003
- 2003-05-13 US US10/436,609 patent/US6989395B2/en not_active Expired - Lifetime
-
2006
- 2006-09-21 CY CY20061101365T patent/CY1105238T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2221795C2 (ru) | Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения | |
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2214400C2 (ru) | Производные 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества | |
| RU2201921C2 (ru) | Производные замещенного фенила и фармацевтическая композиция на их основе | |
| RU2000100951A (ru) | Имидазолил-циклические ацетали | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| RU2436780C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| RU2209813C2 (ru) | Производные пиридазина, лекарственные средства на их основе и способ лечения артрита | |
| RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2011105151A (ru) | Азольные соединения | |
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| RU2002114809A (ru) | Производные хиназолина в качестве ингибиторов васкулярного эндотелиального фактора роста (vegf) | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2009139915A (ru) | Производные имидазолидинона | |
| RU2005131165A (ru) | Производные имидазол-4-илэтинилпиридина | |
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| RU2007128085A (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| FR2586679B1 (fr) | Composes heterocycliques, procedes pour leur preparation, et compositions pharmaceutiques les contenant pour inhiber l'enzyme de conversion de l'angiotensine | |
| RU2221788C2 (ru) | Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения | |
| RU2004122427A (ru) | Пирролидин-2-оны в качестве ингибиторов фактора ха | |
| RU2000104870A (ru) | Производные фталазина и терапевтические средства для эректильной дисфункции | |
| RU98119076A (ru) | Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120613 |